Proactive - Interviews for investors

Future Metals NL (ASX:FME) executive chairman Patrick Walta sits down with Jonathan Jackson in the Proactive studio to discuss upcoming drilling at the company's Eileen Bore Copper-Nickel-PGM Project. Preparations are well underway and will start immediately after the current Kimberley wet season ends. The drilling will target potential mineralisation extensions near surface and at depth. Walta also details the results of the company’s recent scoping study and the de-risking and value optimisation work at the Panton Project. FME recently undertook a $3.3 million raise and Walta outlines how and where the funds will be used. Finally, he talks viewers through what shareholders can expect throughout 2024.

#ProactiveInvestors #FutureMetals #ASX #CriticalMinerals #Copper #Nickel #PGE

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dr. Raza Bokhari, the Executive Chairman and CEO of Medicus Pharma, discussed the company's recent milestone of submitting the phase two clinical protocol to the FDA during an interview with Steve Darling from Proactive.

Medicus Pharma is a clinical-stage holding company listed on the Toronto Stock Exchange that specializes in identifying and investing in novel therapeutic assets, with a primary focus on advancing non-invasive treatments for skin cancers, particularly basal cell carcinoma.

Dr. Bokhari expressed his enthusiasm for the progress made since the fall of the previous year, highlighting the completion of a phase one trial and the initiation of a phase two trial in pursuit of FDA approval. He emphasized the company's strategy to accelerate through the FDA trial process, aiming for fast-track designation and eventual commercialization.

Medicus Pharma's recent participation in the Biotech Showcase at the JP Morgan conference garnered positive feedback and attention. Furthermore, the company's expansion to the Frankfurt exchange aligns with its ambitious plans for a busy and productive 2024, with hopes of crossing borders and uplifting to NASDAQ.

As Medicus Pharma navigates these significant milestones, Dr. Bokhari reiterated the company's commitment to creating sustainable shareholder value and the exciting opportunities on the horizon in the field of non-invasive skin cancer treatments.

#proactiveinvestors #medicuspharmaltd #tsxv #mdcx #fda #clinicaltrials

Pharma #SkinCancerTreatment #FDAApproval #ClinicalTrials #BiotechShowcase #HealthcareInnovation #MedicalResearch #CancerTherapy #InnovativeMedicine #MedicalBreakthrough #RazaBukhari #HealthTech #FrankfurtExchange #NASDAQListing #InvestmentOpportunity #BioTechNews #MedicalAdvancements #PatientCare #HealthScience #ScienceAndTechnology #StockMarket #MedicalUpdates #CorporateAchievements #GlobalHealthcare #2024Outlook#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has announced they plan to collaborate with Enterin, which is a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to its key intermediates and active pharmaceutical ingredients or API’s.

Savile told Proactive Enterin recognized the need to employ more sustainable methods to manufacture its key development targets at reduced cost and less waste and sought Willow's expertise in developing and scaling biobased processes. The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale. The development phase of this funded collaboration is expected to last approximately three months.

In 2024, the company aims to transition its research and development programs into commercial revenue, emphasizing the execution of commercial agreements, advancing technology, and expanding its innovator partnerships. Savile underscored the goal of achieving these milestones without increasing overhead. The interview reflects Willow Biosciences' commitment to strategic growth and transformative solutions in the biotechnology sector. Stay tuned for more exciting developments from this innovative company led by Dr. Chris Savile, shaping the future of bioscience.

#proactiveinvestors #willowbioscienceinc #tsx #wllw #otcqb #cansf #bioscience #biotech #BioTechNews #InnovationInHealth #UnterenCollaboration #Biotechnology #CEOInterview #HealthcareRevolution #NeurodegenerativeTherapeutics #MetabolicDisorders #CommercialAgreements #TechnologyAdvancements #BiotechGrowth #2024Plans #BioBasedSolutions #HealthTech #ScienceInnovation #ResearchAndDevelopment #CostEfficiency #TransformativeManufacturing #Corticosteroids #InnovatorPartnerships #Biopharmaceuticals #BioScienceFuture #RNDPrograms #HealthTech2024#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Cannara Biotech Inc CFO Nicholas Sosiak joined Steve Darling from Proactive to provided valuable insights into the company's success in the cannabis industry during an interview with Steve Darling from Proactive. Cannara, based in Montreal, Canada, is a licensed producer with two facilities totaling 1.6 million square feet, with a strong focus on quality and cost-efficiency, thanks in part to Quebec's low electricity costs.

Sosiak discussed the company's strategic acquisitions, including the purchase of a 1 million square foot cannabis facility for $27 million, significantly below its initial cost. Cannara Biotech Inc. has also developed three in-house brands: Tribal, Nugs, and Orchid CBD, each catering to specific market niches. The company places a strong emphasis on consistency and quality to drive brand loyalty among consumers.

As CFO, Sosiak combines his financial expertise with a passion for the cannabis industry. His leadership has contributed to the company's impressive 60% increase in net revenue. Looking ahead to 2024, Cannara Biotech plans to capitalize on its existing markets, introduce new products, and expand into untapped regions. Sosiak expressed optimism about the potential for international growth, particularly in the US market, once regulatory barriers are addressed.

Cannara Biotech Inc. is currently traded on the TSXV (LOVE) and OTCQB (LOVFF), with plans to enhance visibility among US investors in the future. The interview highlighted the company's robust growth strategies and the dual role of its CFO in financial management and product development, setting a positive trajectory for Cannara Biotech's continued success in the cannabis industry.

#proactiveinvestors #cannarabiotechinc #tsxv #love #otcqb #lovff #invest #investing #investment #investor CannabisIndustry #FinancialSuccess #CBDProducts #CannabisInnovation #CFOInsights #MontrealCannabis #GrowWithCannara #QualityCannabis #CannabisGrowth #CanadianLP #CannabisInvestment #StrategicAcquisitions #ProductInnovation #CannabisBusinessTalk #MarketExpansion #BrandLoyalty #CannabisRevenue #InvestingInCannabis #FutureOfCannabis #SustainableGrowth #CannabisLeadership #CannabisMarketTrends #GlobalCannabis #CannabisSuccessStories #stockmarket #stocks #stock #stockmarketnews

ARway.ai Chief Executive Officer Even Gappelberg joined Steve Darling from Proactive to share exciting news that the company has signed a new developer deal with F3Geomatic Solutions, a distinguished geospatial modeling and mapping agency based in Cuervo, Texas.

Through this partnership, F3Geomatic Solutions and ARway.ai aim to provide seamless, accurate, and immersive tailored geospatial solutions for a wide range of applications, including museums, trade shows, and local governments. This collaboration will create unparalleled user experiences by leveraging ARway's innovative technology and F3Geomatic's expertise in geospatial modeling and mapping.

Gappelberg also highlighted the significant market opportunity arising from the introduction of "Apple Vision Pro." This development is expected to catalyze a substantial transformation within the augmented reality and spatial computing industry. ARway.ai is well-positioned to capitalize on this opportunity, as their ARway app is proudly available in the new spatial computing Vision Pro app store.

Furthermore, ARway.ai's strategic focus on indoor navigation and recent advancements in AR glasses integration align perfectly with the industry's overarching shift towards 3D/AR. This positions the company for continued growth and success in the augmented reality and spatial computing space.

The partnership with F3Geomatic Solutions and ARway.ai's presence in the Vision Pro app store reflect the company's commitment to innovation and its role in shaping the future of augmented reality and spatial computing.

#proactiveinvestors #arwaycorporation #cse #arwy.ai #otc #arwyf #wayfinding

#AugmentedReality #AppleVisionPro #F3Geomatics #ARTechnology #SpatialMapping #TechInnovation #CEOInterview #ARWayUpdates #GeospatialSolutions #TechEnthusiast #ARBusiness #FutureTech #DigitalMapping #AppleInnovation #ARHeadsets #TechIndustryBuzz #InnovationLeadership #ARExperience #DigitalTransformation #AppleLaunch #MarketTrends #ARApplications #IndustryInsights #EvanGappelbergInterview

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

22nd Century Group new CEO Larry Firestone joined Steve Darling from Proactive to discuss his role and the company's strategic direction during an interview with Steve Darling from Proactive. 22nd Century Group is an agricultural biotech firm specializing in tobacco harm reduction and developing low-nicotine content plants for cigarettes. Notably, the company received FDA authorization for modified risk tobacco products in December 2021, with its flagship brand, VLN (Very Low Nicotine), aimed at addressing smoking-related health issues.

Firestone emphasized the strategic shift the company is undergoing, which includes streamlining operations, divesting non-core assets such as the hemp cannabis business, and refocusing solely on the tobacco sector. The company's primary goal for 2024 is achieving financial self-sustainability, with a focus on cost optimization, gross margin improvement, and streamlining the overhead structure.

22nd Century Group is also committed to expanding its presence in established markets, particularly in the United States, and delivering its core products. Firestone's leadership will play a crucial role in guiding the company through these transformative changes and positioning it for growth and success in the coming years.

This strategic shift and renewed focus on tobacco harm reduction reflect 22nd Century Group's commitment to addressing health-related issues associated with smoking and its determination to make a positive impact in the tobacco industry.

#proactiveinvestors #22ndcenturygroupinc #nasdaq #xxii

#LarryFirestone #TobaccoHarmReduction #FDAApproval #VLNBrand #CEOInsights #BusinessTransformation #CorporateStrategy #TobaccoInnovation #NicotineReduction #HealthandWellness #FinancialSustainability #MarketExpansion #SmokingCessation #AgriculturalBiotech #CorporateLeadership #2024Goals #GrossMarginImprovement #StreamliningOperations #InvestorUpdate #TobaccoIndustry #ProductInnovation #CorporateReshaping #ExclusiveInterview #FutureOfTobacco

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) CEO Christopher von Jako speaks to Thomas Warner from Proactive after the medical imaging technology company announced that NUKEM Isotopes GmbH recently increased its stake in Polarean to over 10%, marking a shift in the company's shareholder dynamics.

Von Jako explains that NUKEM, a key player in the trading of stable isotopes used in various industries including medical imaging, has been a long-term partner of Polarean. They supply xenon-129 gas, a critical component of Polarean's functional MRI product.

Von Jako frames it as a strong vote of confidence in Polarean's technology and future, describing it as a "clear indication of interest and belief in the company and the technology."

Currently, von Jako is focusing on attending the annual 129Xe MRI Clinical Trials Consortium in Florida, a significant event for discussing scientific and clinical applications of their technology.

He goes on to say that Polarean's primary goals for 2024 include driving utilisation, expanding their user base, improving reimbursement structures, and pursuing further label expansion. The relationship with NUKEM is seen as a cornerstone in these efforts, as Polarean looks forward to a promising year ahead.

#PolareanImaging #ChristopherVonJako #MedicalImaging #MRI #NuclearIsotopes #HealthcareTechnology #MedicalDevices #Xenon129 #FunctionalMRI #HealthcareInnovation #InvestmentNews #ShareholderUpdates #MedicalIndustry #HealthTech #Radiology #ClinicalApplications #ImagingTechnology #BiotechInvestments #HealthcarePartnerships #ProactiveInterviews #ProactiveInvestors #Polarean #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In an unprecedented surge, newly launched Bitcoin Exchange-Traded Funds (ETFs) have skyrocketed in trading volumes, hitting over $10 billion in just the initial three days. This explosive debut, led by financial giants such as BlackRock Inc, Grayscale, Fidelity, and VanEck, marks a significant milestone in cryptocurrency trading. Despite this surge in ETF activity, Bitcoin's spot prices remain subdued, indicating a potentially shifting landscape in the digital currency market.

Key players like the BlackRock iShares Bitcoin Trust (IBIT) and Grayscale's Bitcoin Trust (GBTC) are at the forefront of this trading frenzy. However, GBTC has seen substantial outflows, suggesting a market inclination towards more competitively priced options. Contrasting Bitcoin's sluggish spot performance, Ethereum shows resilience with an over 8% gain against the US dollar.

Proactive research analyst John Savin speaks to Thomas Warner after publishing a new research note on pharmaceutical group Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF).

Savin gives a preview of what readers will find in the latest note, highlighting OCT's successful completion of the initial trial phase of OCT461201 which confirmed its promising drug profile. The next step for "201" is a comprehensive multiple ascending dose study spanning 14 days, which will commence in mid-2024. This study, critical for advancing to Phase 2 trials, will involve two distinct dosage levels and is expected to yield results by late 2024 or early 2025.

Additionally, OCT is developing a second product targeting severe facial nerve pain. This product is anticipated to enter trials in Australia, subject to funding availability.

Savin highlights that OCT's advancement to clinical trials is a crucial milestone, reflecting the company's robust position in cannabinoid research. However, both studies' initiation hinges on OCT's ability to secure funding in the first half of 2024.

Savin expresses optimism for OCT's journey ahead, with the biotech firm set to start Phase 2 studies in 2025 and explore US market opportunities.

#OxfordCannabinoidTechnologies #CannabinoidResearch #BiotechIndustry #UKBiotech #ClinicalTrials #PharmaceuticalResearch #MedicalCannabis #CannabinoidTherapy #HealthcareInnovation #JohnSavin #ProactiveResearch #DrugDevelopment #Phase2Trials #BiotechFunding #MedicalResearch #Cannabinoids #OCT201S #TrigeminalNervePain #BiotechAdvancements #HealthSector

#ProactiveInvestors #health #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

US Gold Corp (NASDAQ:USAU) Founder Edward Karr speaks to Thomas Warner from Proactive upon his return from the 2024 edition of the Future Minerals Forum 2024, held in Riyadh.

Karr explains that attendance at the event has ballooned in response to increasing demand for critical minerals necessary for decarbonising the global economy, and become a highly important feature of the mining calendar.

He highlights keen interest in the market in US Gold Corp's CK Gold Project in Southeast Wyoming, which is currently awaiting approval for its permit to mine application.

Market interest in both gold and copper opportunities are notably high at the moment, which Karr sees as a major tailwind for US Gold Corp on its journey toward production in Wyoming.

He concludes by saying that the permit approval is the primary focus of the business this year, expressing confidence about the process and telling viewers to "stay tuned" for updates from the Project.

#ProactiveInvestors #gold #copper #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews